Honeywell announced that it has signed a long-term supply agreement with DevPro Biopharma related to the use of Honeywell’s Solstice Air HFO-1234ze in DevPro’s DP007 albuterol metered dose inhaler. Earlier this year, DevPro and CDMO Bespak announced that they were collaborating on development of the LGWP propellant MDI. Recipharm, which later spun out Bespak, and Honeywell announced in August 2023 that they were working together on development of MDIs with Solstice Air.
Honeywell has also announced the planned spin out of its Advanced Materials business, including Solstice Air. The company says that it expects to spin that business out to shareholders by late 2025 or early 2026.
According to the announcement, clinical trials of the DevPro MDI are also expected to begin in 2025, with a launch anticipated in 2027. DevPro CEO Colin Reisner commented, “There’s a pressing need to develop an albuterol inhaler that reduces environmental impact while maintaining its efficacy in treating respiratory conditions. By transitioning to low-carbon propellant alternatives through our supplier relationship with Honeywell, we’re excited to accelerate development on this groundbreaking product.”
Honeywell Sustainability and Decarbonization business President Jeff Dormo said, “Solstice Air will play a critical role in helping to ensure DevPro Biopharma’s life-saving devices are both effective and aligned with environmental goals. By continuing to research and develop lower carbon emission technology, Honeywell is committed to driving innovation that not only enhances health outcomes but also protects our planet for future generations.”
Read the Honeywell press release on the DevPro agreement.
Read the Honeywell press release on the spin off.
